UPDATE REGARDING POSSIBLE OFFER BY ENDEAVOUR MINING CORPORATION ("ENDEAVOUR")

PERTH, AUSTRALIA / ACCESSWIRE / December 18, 2019 / Centamin today provides an update in relation to the unsolicited conditional proposal from Endeavour regarding a potential all share combination (the "Proposal").

Since it was approached by Endeavour in November, Centamin has repeatedly made clear to Endeavour that it is willing to facilitate a reciprocal exchange of due diligence information in order to better assess the value to shareholders of the potential combination. To allow that exchange of information to take place, Centamin proposed that a non-disclosure agreement ("NDA") be executed.

Endeavour declined to enter into an NDA and instead made a voluntary announcement which, under the City Code on Takeovers and Mergers (the "Code"), triggered an automatic and mandatory deadline of 31 December (the "PUSU Deadline") for Endeavour to either announce a firm intention to make an offer for Centamin under Rule 2.7 of the Code or announce that it does not intend to make an offer for Centamin.

On 10 December, the parties executed an NDA and the Chairman of Centamin and CEO of Endeavour met and during that meeting, which took place on 14 December, it was agreed that the parties would conduct reciprocal due diligence in order to fully assess the value to shareholders of the potential combination as a precursor to any further negotiations.

Notwithstanding that the basis of engagement has been agreed and all preconditions to information flow in either direction, including a standstill having been satisfied, Endeavour has now indicated that it will not provide the information that Centamin has requested unless and until Centamin agrees to an extension of the PUSU Deadline. Without Endeavour providing information that is core to the assessment of value, such as its financial model, Centamin cannot properly assess the proposed combination.

The Centamin Board is disappointed that despite its efforts at constructive engagement, Endeavour has repeatedly refused to engage in a proper manner. The unsolicited approach from Endeavour has created an intense period of uncertainty for all of the Company's stakeholders. Therefore, the Board of Centamin believes that Endeavour should, without further delay, enter into substantive reciprocal due diligence.

The Company will determine whether to seek an extension of the PUSU Deadline following its review of any information forthcoming from Endeavour.

The Board continues to advise shareholders to take no action in respect of Endeavour's Proposal.

This announcement has been made without the consent of Endeavour. The person responsible for the release of this announcement on behalf of Centamin is Josef El-Raghy, Chairman.

For more information, please visit the website www.centamin.com or contact:

Centamin plc
Ross Jerrard, Interim Chief Executive Officer and Chief Financial Officer
Alexandra Carse, Investor Relations
+44 (0) 7700 713 738

BofA Securities
George Close-Brooks
Geoff Iles
Joshua Maguire
Charles Pitt Ford
+44 (0)20 7628 1000

BMO Capital Markets
Gary Mattan
Tom Rider
Pascal Lussier-Duquette
Neil Elliot
+44 (0)20 7236 1010

Buchanan Communications
Bobby Morse
Chris Judd
+ 44 (0)20 7466 5000

As previously stated, in accordance with Rule 2.6(a) of the Code, Endeavour is required, by not later than 5.00 p.m. on 31 December, to either announce a firm intention to make an offer for Centamin in accordance with Rule 2.7 of the Code or announce that it does not intend to make an offer, in which case the announcement will be treated as a statement to which Rule 2.8 of the Code applies. This deadline can be extended with the consent of the Panel in accordance with Rule 2.6(c) of the Code.

Important Notice

Merrill Lynch International ("BofA Securities"), a subsidiary of Bank of America Corporation, which is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority in the United Kingdom, is acting exclusively for Centamin in connection with the matters set out in this announcement and for no one else and will not be responsible to anyone other than Centamin for providing the protections afforded to its clients or for providing advice in relation to the subject matter of this announcement or any other matters referred to in this announcement.

BMO Capital Markets Limited ("BMO"), which is authorised and regulated in the United Kingdom by the Financial Conduct Authority, is acting exclusively for Centamin and no one else in connection with the above and will not be responsible to anyone other than Centamin for providing the protections offered to clients of BMO nor for providing advice in relation to the subject matter of this announcement or any other matters referred to in this announcement.

Dealing Disclosure Requirements of the Code

Under Rule 8.3(a) of the Code, any person who is interested in 1% or more of any class of relevant securities of an offeree company or of any securities exchange offeror (being any offeror other than an offeror in respect of which it has been announced that its offer is, or is likely to be, solely in cash) must make an Opening Position Disclosure following the commencement of the offer period and, if later, following the announcement in which any securities exchange offeror is first identified. An Opening Position Disclosure must contain details of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any securities exchange offeror(s). An Opening Position Disclosure by a person to whom Rule 8.3(a) applies must be made by no later than 3.30 pm (London time) on the 10th business day following the commencement of the offer period and, if appropriate, by no later than 3.30 pm (London time) on the 10th business day following the announcement in which any securities exchange offeror is first identified. Relevant persons who deal in the relevant securities of the offeree company or of a securities exchange offeror prior to the deadline for making an Opening Position Disclosure must instead make a Dealing Disclosure.

Under Rule 8.3(b) of the Code, any person who is, or becomes, interested in 1% or more of any class of relevant securities of the offeree company or of any securities exchange offeror must make a Dealing Disclosure if the person deals in any relevant securities of the offeree company or of any securities exchange offeror. A Dealing Disclosure must contain details of the dealing concerned and of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any securities exchange offeror(s), save to the extent that these details have previously been disclosed under Rule 8. A Dealing Disclosure by a person to whom Rule 8.3(b) applies must be made by no later than 3.30 pm (London time) on the business day following the date of the relevant dealing.

If two or more persons act together pursuant to an agreement or understanding, whether formal or informal, to acquire or control an interest in relevant securities of an offeree company or a securities exchange offeror, they will be deemed to be a single person for the purpose of Rule 8.3.

Opening Position Disclosures must also be made by the offeree company and by any offeror and Dealing Disclosures must also be made by the offeree company, by any offeror and by any persons acting in concert with any of them (see Rules 8.1, 8.2 and 8.4).

Details of the offeree and offeror companies in respect of whose relevant securities Opening Position Disclosures and Dealing Disclosures must be made can be found in the Disclosure Table on the Takeover Panel's website at www.thetakeoverpanel.org.uk, including details of the number of relevant securities in issue, when the offer period commenced and when any offeror was first identified. You should contact the Panel's Market Surveillance Unit on +44 (0)20 7638 0129 if you are in any doubt as to whether you are required to make an Opening Position Disclosure or a Dealing Disclosure.

The defined terms used in this section "Dealing Disclosure Requirements of the Code" are defined in the Code which can be found on the Takeover Panel's website.

Publication on Website

A copy of this announcement will be made available (subject to certain restrictions relating to persons resident in restricted jurisdictions) at www.Centamin.com no later than 12:00 noon (UK time) on 19 December 2019 (being the business day following the date of this announcement) in accordance with Rule 26.1(a) of the Code. The content of the website referred to in this announcement is not incorporated into and does not form part of this announcement.

Forward-looking Statements

This announcement (including information incorporated by reference) contains "forward-looking statements" and "forward-looking information" under applicable securities laws (collectively, "forward-looking statements"), including statements relating to the Proposal. Generally, these forward-looking statements can be identified by the use of forward-looking terminology such as "believes", "expects", "expected", "budgeted", "forecasts" and "anticipates". Although Centamin believes that the expectations reflected in such forward-looking statements are reasonable, Centamin can give no assurance that such expectations will prove to be correct. Forward-looking statements are prospective in nature and are not based on historical facts, but rather on current expectations and projections of the management of Centamin about future events, and are therefore subject to known and unknown risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information or statements. Forward-looking statements contained herein are made as of the date of this announcement and the Company disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or results or otherwise. Accordingly, readers should not place undue reliance on forward-looking statements.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: Centamin PLC

ReleaseID: 570638

CENTRALISATION OF SAMPLE COMPOUNDS IN TOULOUSE PROVIDES GREATER EFFICIENCY FOR SANOFI'S SMALL MOLECULE DRUG DISCOVERY EFFORTS
LATEST DISPENSING TECHNOLOGY WILL HELP OPTIMISE COMPOUND ACCESS ACROSS GLOBAL RESEARCH SITES

HAMBURG, GERMANY / ACCESSWIRE / December 18, 2019 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced plans to extend its sample management activities through an expansion of its service agreement with Sanofi.

Evotec has had a successful track record of managing Sanofi's powder compounds at its Toulouse site since 2015. Under the terms of the new agreement, Sanofi will transfer its liquid compounds to Evotec in Toulouse over the next 2 years. Evotec will house the Sanofi compound collections in Toulouse combining central storage efficiency with sample delivery supported by next generation, cutting-edge technologies e.g. acoustic tubes. This expanded strategy will deliver cost efficiencies through the minimisation of redundancies and realisation of synergies between sites.

Dr Craig Johnstone, Chief Operating Officer of Evotec, commented: "We are pleased to expand our relationship with Sanofi. It's a significant step forward to synergise and centralise core drug discovery processes for better efficiency and to enhance our sample management expertise with the latest dispensing technologies. We look forward to continuing to deliver the highest quality sample management service for Sanofi and for our other clients."

About Evotec's Sample Management
The demand for organised data storage and management concepts to maintain, collect and distribute compounds has grown significantly. Evotec is uniquely qualified in delivering its customers small and large molecule library management needs through over a decade of being the world's leading sample management operation. Starting from a single site in South San Francisco in 2004 primarily serving the US, Evotec expanded its operational presence in sample management in 2013, and again in 2015, by adding capacity and capabilities in Branford, Connecticut and Toulouse, France. These facilities are strategically positioned to support the strong presence of Evotec's drug discovery services across the USA and Europe.

ABOUT EVOTEC SE
Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide and our more than 2,900 employees provide the highest quality stand-alone and integrated drug discovery and development solutions. We cover all activities from target-to-clinic to meet the industry's need for innovation and efficiency in drug discovery and development (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuronal diseases, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. On this basis, Evotec has built a broad and deep pipeline of approx. 100 co-owned product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term alliances with partners including Bayer, Boehringer Ingelheim, Celgene, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, UCB and others. For additional information please go to www.evotec.com and follow us on Twitter @Evotec.

FORWARD LOOKING STATEMENTS
Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.

Contact Evotec SE:
Gabriele Hansen, SVP Corporate Communications, Marketing & Investor Relations, Phone: +49.(0)40.56081-255, gabriele.hansen@evotec.com

SOURCE: Evotec AG

ReleaseID: 570637

NEW YORK, NY / ACCESSWIRE / December 18, 2019 / Today, CBD (or cannabidiol) is taking over the wellness world.

There's a very likely chance that you have come across the acronym online, in magazines, or on lifestyle blogs. Before it became popular, no one is openly talking about it, what it can do and why it's important. Today, it's different. More and more people are discussing and trying it out themselves. In fact, you can get lattes, chocolates, meals or oils infused with CBD and a lot of people online are not only talking about CBD and its benefits but also championing it.

CBD has a wide array of benefits and impacts on industries such as health, wellness, and beauty that it's now slowly but surely creeping in different markets from all around the world. In the States to Europe, and even, in some Southeast Asian countries where it's legal. With the growing industry and the quick manufacturing of CBD products, the industry is now tainted with fake products that promise you nothing but make you sick.

So one should ought to know what are the products you need to trust in the market. Despite the rise of these fake businesses, there are some reputable companies that thrive in the industry. Take a look at cbdMD.

cbdMD continues to lead the industry with the variety of products and concentrations that they offer at affordable prices. Their current products include CBD tinctures, CBD capsules, CBD sleep aids, CBD gummies, CBD topicals, and CBD bath bombs. And they are committed to providing the best quality for the years to come.

So what makes cbdMD's CBD products stand out from the rest?

cbdMD use exclusively 100% organic, USA-grown hemp

cbdMD plants their hemp in Kentucky, and there's a reason for that.

Kentucky has the most pristine growing conditions in the world. It has a near-perfect climate for year-round which means that its soil is rich in nutrition perfect for hemp planting and growth. Hemp grown in the U.S. is held to a much higher standard than poorly sourced international hemp. cbdMD also takes pride in their unique manufacturing process. Supporting wellness for all and passionate about changing lives with their products, the company sows each seed by hand to ensure quality implanting.

cbdMD's core belief is quality over quantity. Through this, they can ensure you can trust the powerful properties of the CBD you're putting in your body.

All the products further undergo third-party testing through independent labs.

cbdMD cares so much for their customers.

They don't just stop with ensuring the best, high-quality CBD oil through rigorous testing throughout the entire manufacturing and production process. cbdMD and its products further undergo additional and extensive third-party testing through independent labs so they can confidently guarantee their products are free of synthetic additives. Not only that, cbdMD takes pride in being fully transparent and welcomes you to view the independent third-party testing results and you can do it online.

With a CBD product that guarantees safety and quality like no other, you definitely need to try cbdMD yourself.

Free shipping within the U.S.

If you're living in the United States, you can order cbdMD's CBD products for free. And if you're not satisfied with your purchase, they also have a 30-day money-back guarantee that only cbdMD offers. So, rather than spending more money on shipping, you can save more when you shop from cbdMD's website.

You can make your first order at www.cbdmd.com and watch as cbdMD's quality CBD oil products transform your life. For more information contact pr@cbdmd.com

SOURCE: cbdMD

ReleaseID: 570635

HONG KONG, CHINA / ACCESSWIRE / December 18, 2019 / One of China's top 100 internet companies with a tri-core "Video+" business focus, V1 Group Limited ("V1 Group" or the "Company", together with its subsidiaries, the "Group"; stock code: 00082.HK), today announced that Soccer Manager 2020 ("夢幻足球世界"), an official soccer management mobile game from the Soccer Manager series, has been released by its wholly-owned subsidiary, Beijing Crazy Sports Management Company Limited ("Crazy Sports"), which is now available on Apple App Store and Google Play Store. The game is the official Chinese version of the latest Soccer Manager 2020. Overseas, the game has been fully released and was recommended by App Store and Google Play in 22 countries around the world. The game is now Top 5 of the Hong Kong App Store's Sports Games category, and is Top 100 in the overall game ranking.

The latest release is the 16th edition of the Soccer Manager series. Its preceding version, Soccer Manager 2019, was highly recommended by App Store and Google Play in more than 200 countries and has accumulated more than 40 million players globally. More than one million Chinese players are playing on the authorised official Chinese version.

The soccer management mobile game features a vast database where players can identify and choose their own team members from more than 200 thousand soccer stars from over 800 clubs in 33 countries. The database is linked to the Soccer Wiki website to achieve real-time updates. On the pitch, players can arrange their own formations and adapt different strategies concurrently to get a complete match experience.

The size of Soccer Manager 2020 is less than 90MB, meaning that it takes up only a relatively small portion of mobile storage. The game can be downloaded for free, so that players can start playing without prior payment. As the game's distributor, Crazy Sports not only introduced the official Soccer Manager into the country, but also created the full Chinese version tailor-made for the Chinese market, such that even leisure and new players can enjoy the soccer game.

The game is now available for download on App store, TapTap and Crazy Sport's official website. Players can also join in on the conversation on the Soccer Manager 2020 official forum at http://bbs.crazysports.com.

– End –

About V1 Group Limited

Founded in 2005, V1 Group Limited became a listed company on the Main Board of the Hong Kong Stock Exchange in 2006 and is the first China online video company to be listed in Hong Kong. The Group has a "Video+" business focus. Supported by 5G technology, it aims to build an ecosystem around news video community, sports video community and video new retail. In 2016, V1 Group successfully transformed from a new media enterprise into an internet-based new economy entity. Leveraging on its diverse business covering the media, connected living, internet financing, advanced internet technology as well as other sectors, the Group has become one of the top 100 internet companies in China. the Company made a full acquisition of Fengkuang Tiyu ("Crazy Sports") in 2018 to accelerate the construction of its "Video+" sports community business model, creating a strong overall revenue growth momentum for the Group.

For more information, please visit ir.v1group.com.hk.

Document: http://n.eqs.com/c/fncls.ssp?u=XVLOOSSJKO
Document title: Chinese Mobile Version of Soccer Manager 2020 Now Available on App Store and Google Play

18/12/2019 Dissemination of an Announcement, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.

Media archive at www.todayir.com

SOURCE: V1 Group Ltd

ReleaseID: 570634